PD-L1 cervical cancer trial with chemotherapy and possible bevacizumab
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 3 study tests GLS-010 added to standard platinum chemotherapy, with or without bevacizumab, as a first treatment for cervical cancer that has persisted, come back, or spread. If you have PD-L1–positive tumors, the goal is to improve how long people can control the cancer compared with standard chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign informed consent and be willing to follow study visits and procedures.
- You must be a woman age 18 to 75, with good day-to-day function (ECOG 0–1).
- Your cervical cancer must be confirmed as PD-L1 positive (CPS 1 or higher) and be squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- You should not have had prior medicines for advanced/persistent/recurrent cervical cancer; you also can’t be eligible for cure with surgery or the current combination of chemo + radiation.
- You must have at least one measurable tumor spot on scans, and it must be safe for you to have study medicines based on organ function tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
This Phase 2 study tests whether adding a PD-L1 antibody to chemotherapy helps people with newly diagnosed limited-stage small-cell lung cancer live longer and control the cancer better. It may benefit patients who have not had any prior cancer treatment for SCLC and can meet health and lab requirements.
This trial looks at using a blood test (ctDNA) to guide whether patients with advanced or recurrent cervical cancer can safely reduce their immunotherapy treatment. It aims to maintain effectiveness while lowering side effects.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Hear when a new Persistent, Recurrent, or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.